Broadly neutralizing monoclonal antibodies against influenza A viruses: current insights and future directions
Monoclonal antibodies (mAbs) have become attractive tools for both the treatment and prevention of influenza A viruses due to their ability to target several viral components, which confers broad therapeutic potential. Advances in biotechnology, such as hybridoma technology, phage display technology...
保存先:
| 主要な著者: | , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Frontiers Media S.A.
2026-01-01
|
| シリーズ: | Frontiers in Microbiology |
| 主題: | |
| オンライン･アクセス: | https://www.frontiersin.org/articles/10.3389/fmicb.2025.1738181/full |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|